ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
NCT: NCT06733922 · RECRUITING
Brief Summary
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.
Frequently Asked Questions
What is ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS?
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS is a clinical trial registered under NCT06733922. Current status: RECRUITING.
What is the status of NCT06733922?
The current status of NCT06733922 (ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS) is: RECRUITING.
When did ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS start?
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS started on 2024-11-27.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.